Several targeted trials on drugs that treat fragile X syndrome are under way. But accurate endpoints to measure the drugs’ effectiveness are crucial, argues developmental and behavioral pediatrician Randi Hagerman.
Spectrum: Autism Research News
Large studies on the epidemiology and genetics of epilepsy and autism have uncovered commonalities between the two disorders. But scientists are only beginning to untangle the biological roots of the overlap.
Six strains of mice lacking a gene associated with fragile X syndrome show radically different behaviors though they share the same mutation, researchers reported in January in Autism Research.
A partial mutation that leads to a milder form of fragile X syndrome causes deficits in learning and memory in mice, and alters the connections between their neurons, according to a study published in January in Neurobiology of Disease.
Men with fragile X syndrome have larger brains overall than controls do, but less matter in regions involved in language and social interaction.
Inhibiting the ERK1/2 pathway — which regulates the synthesis of other proteins — can rescue some of the effects of fragile X syndrome, according to a study published 17 November in the Journal of Neuroscience. The ERK pathway could provide a novel target for fragile X therapies.
Minocycline, an antibiotic approved to treat various infections including acne, can increase vocalizations and provide long-lasting improvements in anxiety in a fragile X mouse model, according to two posters presented at the Society for Neuroscience annual meeting in San Diego.
Lowering the levels of proteins associated with Alzheimer’s disease can improve symptoms of fragile X syndrome in mice, according to a poster presented Wednesday at the Society for Neuroscience annual meeting in San Diego.